Information Provided By:
Fly News Breaks for September 6, 2019
LIVN
Sep 6, 2019 | 12:27 EDT
Piper Jaffray analyst Matt O'Brien spoke to LivaNova's management following CMS approval the company's treatment-resistant depression, or TRD, protocol, and he views the updates positively and continues to see TRD as "one of the most exciting and large pipeline opportunities" for the company. O'Brien was also positive on the company's turnaround of its core Neuromod business due to its "solid" Q2 results, and maintained an Overweight rating and $90 price target on LivaNova shares.
News For LIVN From the Last 2 Days
There are no results for your query LIVN